<DOC>
	<DOCNO>NCT00967213</DOCNO>
	<brief_summary>The purpose study evaluate change preferential hyperacuity perimeter ( PHP ) fundus autofluorescence ( FAF ) patient neovascular age-related macular degeneration receive combination ranibizumab ( LucentisTM ) verteporfin ( Visudyne® ) therapy</brief_summary>
	<brief_title>Combination Ranibizumab Verteporfin Therapy Neovascular Age-related Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>Verteporfin</mesh_term>
	<criteria>Signed write informed consent Age ≥ 50 year old Patients primary active subfoveal CNV secondary AMD Baseline bestcorrected visual acuity ( BCVA ) study eye 20/40 20/400 use ETDRS chart Characteristics AMD lesion predominantly minimally classic , occult absence prior subfoveal treatment macular disease total lesion size ≤ 9 optic disc area , CNV component ≥ 50 % lesion ( unless serous pigment epithelial detachment present , case &lt; 50 % CNV acceptable ) active choroidal neovascularization leakage submacular blood &lt; 50 % subretinal fibrosis &lt; 25 % total lesion additional eye disease could compromise VA CNV unrelated AMD ocular inflammation vitreous hemorrhage retinal hemorrhage ( AMD relate submacular blood ) &gt; 1 disc area intraocular surgery ≤ 1 month day 0 uncontrolled glaucoma prior treatment verteporfin PDT laser photocoagulation intervention AMD previous treatment externalbeam radiation therapy transpupillary thermotherapy history vitrectomy</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>